IP Library Granted Patent US 11,268,116
Granted Patent B2
US 11,268,116 · App. 15/941,057 · Granted Mar 8, 2022

Endonuclase-assisted isothermal amplification using contamination-free reagents

Inventors: Robert Scott Duthie (Schenectady, NY); John Richard Nelson (Clifton Park, NY); Anuradha Sekher (Hillsborough, NJ)
Assignee: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
C12P19/34C12Q1/6844C12Q1/6848
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,268,116
App. No.
15/941,057
Granted
Mar 8, 2022
Kind
B2
Abstract

Disclosed are methods and kits for endonuclease-assisted DNA amplification reaction using decontaminated primer solutions that are pre-treated with a nuclease. Nucleic acid amplification assays that employ nuclease-resistant, inosine-containing primers, endonuclease V enzymes to introduce a nick into a target DNA comprising at least one inosine, and a DNA polymerase to generate amplicons of a target DNA are also disclosed.

Claims (17)

1. A method of producing at least one amplicon based on a target DNA comprising:

(a) providing the target DNA;

(b) providing a primer solution comprising at least one exonuclease-resistant, inosine-containing primer, wherein said inosine-containing primer comprises at least one inosine residue or inosine analogue in its sequence;

(c) generating a DNA amplification reaction mixture by mixing together the target DNA, the primer solution, at least one 5′→3′ exonuclease-deficient DNA polymerase having a strand displacement activity, and at least one endonuclease that is capable of nicking an inosine-containing strand of a double stranded DNA at a residue 3′ to an inosine residue or inosine analogue; and

(d) incubating the DNA amplification reaction mixture to amplify at least one portion of the target DNA using the at least one exonuclease-resistant, inosine-containing primer to produce the at least one amplicon,

wherein the nuclease-resistant, inosine-containing primer comprises a phosphorothioate linkage at the 3′ side, or both the 3′ and 5′ side of and adjacent to the inosine residue or inosine analogue.

2. The method claim 1 , wherein the primer solution further comprises free deoxynucleotide triphosphates (dNTPs).

3. The method of claim 2 , wherein the primer solution further comprises DNA amplification buffer, formamide, single stranded DNA binding protein, ethylene glycol, Ficoll or combinations thereof.

4. The method of claim 1 further comprising decontaminating the primer solution, prior to generating the DNA amplification reaction mixture, by treating the primer solution with an exonuclease to remove any contaminating nucleic acids.

5. The method of claim 4 , further comprising inactivating the exonuclease in the primer solution after removal of any contaminating nucleic acids prior to generating the DNA amplification reaction mixture, and wherein optionally the target DNA is amplified under isothermal conditions.

6. The method of claim 1 , wherein the inosine residue or inosine analogue of the nuclease-resistant, inosine-containing primer is located at least 4 nucleotides downstream of the 5′ terminal nucleotide.

7. The method of claim 6 , wherein the inosine residue or inosine analogue of the nuclease-resistant, inosine-containing primer is located at the penultimate 3′ position.

8. The method of claim 1 , wherein the inosine-containing primer comprises at least 2 adjacent inosine residues or inosine analogues, wherein optionally the inosine residues are located both at the penultimate 3′ position and the 3′ terminal end of the inosine-containing primer.

9. The method of claim 1 , wherein:

i) the at least one 5′→3′ exonuclease-deficient DNA polymerase is selected from 5′→3′ exonuclease-deficient T7 DNA polymerase, 5′→3′ exonuclease-deficient Bst DNA polymerase, 5′→3′ exonuclease-deficient Klenow, 5′→3′ exonuclease-deficient delta Tts DNA polymerase, or combinations thereof;

ii) the primer solution comprises at least one inosine-containing forward primer and at least one inosine-containing reverse primer, wherein both the forward primer and the reverse primer are exonuclease-resistant; or

iii) the at least one nuclease-resistant, inosine-containing primer comprises an extender template.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: GE HEALTHCARE UK LIMITED
To: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
Reel/Frame 054300/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: GENERAL ELECTRIC COMPANY
To: GE HEALTHCARE UK LIMITED
Reel/Frame 053981/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2018
From: DUTHIE, ROBERT SCOTT; NELSON, JOHN RICHARD; SEKHER, ANURADHA
To: GENERAL ELECTRIC COMPANY
Reel/Frame 045393/0559 →
Continuity (4)
Continuation 13965696 · Aug 13, 2013
Continuation In Part 13330745 · Dec 20, 2011
Division 11621703 · Jan 10, 2007
Related Publication 20190062795A1 · Feb 28, 2019